A Single Leaf Signals Autumn | Culture and Gene Editing of HUVECs (Human Umbilical Vein Endothelial Cells)
2026-11-02
1. Cell background
Human umbilical vein endothelial cells (HUVECs) are primary endothelial cells derived from the inner lining of the umbilical vein in newborns. As a routinely discarded tissue following delivery, the umbilical cord provides an almost ethically unrestricted source for HUVEC isolation. By perfusing the venous lumen with collagenase, a highly purified endothelial cell suspension can be obtained, which exhibits relatively easy adherence and robust expansion during in vitro culture.
The core value of HUVECs lies in their primary‑cell status: compared with immortalized endothelial cell lines (such as EA.hy926) or non‑human endothelial cells, HUVECs retain most of the physiological characteristics of vascular endothelium—response to shear stress, inducible expression of leukocyte adhesion molecules, and tube‑formation capability on Matrigel. This makes HUVECs the most widely used human endothelial model in studies of vascular biology, inflammatory mechanisms, angiogenesis, and the evaluation of drug‑induced vascular toxicity.
However, primary‑cell status also entails distinct limitations. HUVECs are a finite cell line that undergoes replicative senescence: with each passage, the cells progressively lose their cobblestone morphology, exhibit reduced proliferative capacity, and experience declining tube‑formation ability. Commonly used primary HUVECs typically sustain 14–15 population doublings in vitro; beyond this window, phenotypic drift and functional decline can substantially confound experimental interpretation. Grasping this principle is the starting point for making informed decisions about HUVEC culture.
At the gene-editing level, the primary nature of HUVECs also poses inherent challenges. Primary cells exhibit low transfection efficiency and limited replicative lifespan, making it difficult to achieve optimal editing outcomes using conventional plasmid‑ or lentiviral‑based approaches. Leveraging CRISPR/Cas9 to generate HUVEC knockout models—targeting genes such as HIF1A, KNDC1, and Arg2—has become a critical strategy for elucidating precise molecular mechanisms and validating therapeutic targets in endothelial cells; however, editing protocols must be tailored to account for the unique characteristics of primary cells.
2. Cell Description
Cell Name : Human Umbilical Vein Endothelial Cells (HUVEC)
Cell source : Isolated from the umbilical vein of newborns. Commercial sources primarily include ATCC’s primary HUVECs (PCS‑100‑010, pooled from 10 donors to minimize batch-to-batch variability) and the immortalized HUVEC‑C cell line (CRL‑1730). Primary HUVECs are typically cryopreserved at passage 2 to ensure high post‑thaw viability and efficient attachment.
Cell morphology : Adheres to the substrate and exhibits a typical Cobblestone-like single layer The cells are polygonal, with well-defined outlines and uniform spreading; they are tightly interlocked, exhibiting pronounced contact inhibition. Short spindle-shaped cells may also appear in vitro, but as long as the monolayer remains intact—without cell overlap or swirling growth patterns—the endothelial morphology is still considered acceptable.
Doubling time The doubling time of primary HUVECs varies with passage number and culture medium; at low passages, it is typically in specialized media such as EGM-2. 24–48 hours , gradually lengthening with the accumulation of CPDL.
Culture conditions
1) Complete culture medium: EGM-2 (endothelial cell-specific medium containing growth factors) or F-12K + 10% FBS (commonly used for the HUVEC-C immortalized cell line)
2) Culture conditions: 37°C, 5% CO₂, saturated humidity incubator
3) Passage ratio: 1:3–1:4
4) Passage frequency: every 2–4 days; passage when confluence reaches 70%–80%.
5) Gelatin (0.25%) or fibronectin; gelatin must be incubated at 37°C for at least 30–60 minutes.
6) Cryopreservation solution: 90% FBS + 10% DMSO
Morphological image :

3. Cellular Characteristics
Adhesion-dependent substrates—failure to inoculate in a bare flask is the primary cause of failure. HUVECs require extracellular matrix support to achieve stable adhesion and spreading. Uncoated cultureware can result in unstable attachment, indistinct cell outlines, and even sheet‑like detachment. Gelatin (0.25%, incubated at 37°C for ≥30 minutes) or fibronectin are standard choices; be sure to remove any residual coating solution before use. Notably, for studies requiring shear‑resistant monolayers, HUVEC monolayers coated with laminin are more robust than those coated with gelatin or fibronectin, facilitating the formation of a shear‑tolerant endothelial barrier.
The generation gap is more important than “how quickly one grows up.” : The functional inflection point of HUVECs does not fully coincide with their proliferation rate. Cells at low passage numbers exhibit a regular morphology and strong tube‑forming capability; however, as passages accumulate, the cells gradually enlarge, their borders become indistinct, and long protrusions emerge, leading to a marked decline in tube‑forming ability. Therefore, primary HUVEC functional assays—particularly tube‑formation experiments—should be performed preferentially using cells from the earliest passages. Low passage number (generally recommended within P6) Even in highly passaged cells that are still proliferating, the reliability of phenotypic interpretation has already diminished.
Highly sensitive to digestion and mechanical forces HUVECs adhere to the culture surface relatively loosely. Prolonged trypsinization—exceeding 2–3 minutes—can damage the cell membrane and reduce cell viability. During media changes, direct flushing onto the cell layer, excessively high centrifugation speeds, or overly vigorous pipetting can all lead to cell edge curling, detachment, or vacuolization. Throughout the process, using pre-warmed (37°C) culture medium and adding it slowly along the dish wall are fundamental practices for minimizing mechanical stress.
Mycoplasma contamination is the most insidious culprit behind deteriorating cell growth. HUVECs are highly susceptible to mycoplasma, but mycoplasma does not cause turbidity in the culture medium. The typical manifestation is Slow proliferation, abnormal morphology, and increased vacuolization Moreover, these signals are easily misinterpreted as indicating “high passage number” or “failed serum.” Once mycoplasma testing is positive, it is advisable to discard the culture and revive early‑passage cells, rather than relying on mycoplasma‑removal agents to “rescue” a cell population that has already been compromised.
The endothelial phenotype requires confirmation by specific markers and cannot be determined solely on the basis of morphology. : The marker panel for HUVEC identification is CD31 (PECAM-1) and vWF In flow cytometric analysis, the CD31-positive rate of purified primary HUVECs can reach 93.1% , vWF immunofluorescence is widely positive. The reported flow cytometric positivity rates for CD31 and CD105 in commercial primary HUVECs are typically ≥95%。
Gating capacity is the “gold standard” of functional state, but it is extremely sensitive to temporal dynamics. : The tube‑formation assay of HUVECs on Matrigel is a classic method for assessing angiogenic capacity, but its success hinges critically on several prerequisite conditions: the cells must be in the logarithmic growth phase, at a sufficiently low passage number, and the Matrigel must be evenly coated and fully polymerized. When the tube‑formation assay fails, the issue often lies not in the “tube formation” step itself, but rather in compromised cell quality or inadequate matrix preparation at earlier stages.
4. Frequently Asked Questions
4.1 Cell Revival
Q: What procedures should be followed during HUVEC recovery to improve the cell attachment rate?
A: After removing the cells from liquid nitrogen, rapidly thaw them in a 37°C water bath (within one minute). Transfer the cell suspension to a centrifuge tube and slowly add pre-warmed culture medium to avoid osmotic shock that could damage the cells. Centrifuge to remove the DMSO, then resuspend the cells in fresh complete culture medium and proceed with seeding. Do not change the medium within 24 hours post‑thaw to allow the cells sufficient time to establish initial attachment; premature medium changes may wash away cells that have not yet adhered. If, after thawing, cell attachment is sparse but no obvious contamination is present, allow the cells to rest for 48 hours before reassessing.
Q: After recovery, a large number of cells are floating, with very few adhering to the surface—what could be the cause?
A: First, systematically check three key steps: whether the coating is adequate (e.g., whether the gelatin is fresh, the incubation time is sufficient, and residual liquid has been thoroughly removed); whether the thawing process is sufficiently rapid (slow thawing can lead to intracellular ice crystal–induced damage); and whether pipetting and centrifugation are performed too vigorously. Serum quality is also a common factor; low‑quality serum or serum that has undergone repeated freeze–thaw cycles can markedly impair HUVEC adhesion.
4.2 Cell Adhesion and Morphology
Q: What should I do if HUVECs do not adhere firmly to the culture surface and detach in sheets after medium change?
A: This is an intrinsic characteristic of HUVECs as primary endothelial cells; the key strategies are matrix coating and gentle handling. Cultureware must be pre-coated with 0.1% gelatin or fibronectin. When changing the medium, gently add the warmed culture medium along the vessel wall, and never directly flush it onto the cell layer. Centrifuge at 1,000 rpm for 3–5 minutes, avoiding excessive speeds that could cause mechanical damage. If adhesion issues arise following a change in a particular serum lot, prioritize investigating the serum.
Q: HUVECs have become elongated and exhibit a vortex-like arrangement—are they undergoing differentiation?
A: HUVECs are not a differentiated cell line, so “differentiation” is not an appropriate term. They typically exhibit an elongated spindle-shaped morphology with a swirling growth pattern; the most critical concern is contamination by fibroblasts or smooth muscle cells. During primary isolation, insufficient collagenase digestion or inadequate differential adhesion can allow contaminating cells to gradually dominate during passaging. Another possibility is senescence‑related morphological changes resulting from excessive passage numbers—cells become larger, their borders blur, and long protrusions may emerge. To distinguish between these two scenarios, perform marker‑based analysis: positivity for CD31 or vWF supports endothelial identity, whereas negativity suggests contamination.
Q: What does the presence of numerous vacuoles in HUVECs indicate?
A: Vacuolization in primary HUVECs requires careful attention. If it occurs at low passage numbers, prioritize investigating over‑digestion, excessive centrifugation, or abnormalities in culture medium osmolarity or pH. If it arises at higher passages (P7 and beyond), vacuolization often coincides with replicative senescence, indicating that the cells have entered a phase of functional decline; such cells are not recommended for further use in tube formation or barrier‑function assays.
4.3 Cell Digestion and Passaging
Q: During digestion, HUVECs tend to clump together and cannot be dispersed by pipetting. How should this be handled?
A: For HUVECs, digestion should be brief rather than prolonged. We recommend using 0.25% trypsin at 37°C for 1–2 minutes; stop the reaction immediately by adding serum‑containing culture medium once cells appear rounded and intercellular spaces have widened under the microscope. Over‑digestion can damage the cell membrane and lead to clonal cell death, while insufficient digestion may result in mechanical injury from vigorous pipetting. After stopping the reaction, gently pipette the cells 2–3 times—there is no need to achieve a completely single‑cell suspension.
Q: What is the appropriate passage ratio?
A: For primary HUVECs, a split ratio of 1:2 to 1:3 is recommended; lower ratios are not advised. At low seeding densities, paracrine signaling between cells is insufficient, leading to slowed growth and an increased likelihood of morphological abnormalities in sparsely populated areas. Passage should be performed when confluence reaches 70%–80%; do not wait until 100% confluence, as excessive density can trigger contact inhibition and morphological disruption, adversely affecting subsequent culture performance.
4.4 Contamination and Serum Batch
Q: The culture medium remains clear, but the cells grow increasingly slowly and their morphology deteriorates—what might be the cause?
A: Mycoplasma contamination is highly suspected. Mycoplasma does not cause turbidity in the culture medium, but it continuously disrupts cellular signaling pathways, manifesting as slow proliferation, increased vacuolization, and morphological abnormalities. We recommend regular testing by PCR or fluorescence-based methods. Once a positive result is obtained, we do not recommend attempting to maintain the culture with clearing agents; instead, it is more prudent to re‑establish the culture using early‑passage cells that are free of mycoplasma.
Q: After switching to a new batch of serum, the HUVEC cells show a marked decline in viability. What should I do?
A: HUVECs are sensitive to variations between serum batches. For a new batch, it is recommended to first conduct small-scale parallel assays—assessing attachment rate, doubling time, and cell morphology—and only proceed with full replacement once no abnormalities are detected. If feasible, consistently using the same serum batch and maintaining an adequate stock is the most straightforward approach to minimizing batch-to-batch variability and ensuring experimental reproducibility.
5. Gene Editing
The core challenge in gene editing of HUVECs lies in their primary cell characteristics: low transfection efficiency, limited replicative lifespan, and difficulty in establishing single-cell clones.
The ceiling of delivery efficiency for plasmid- and lentivirus‑based approaches. Under standard plasmid‑mediated delivery conditions, genome‑editing efficiency in HUVECs is only about 4.5%, far below that observed in model cell lines such as HEK293T. Although lentiviral vectors can enhance delivery efficiency, primary HUVECs exhibit limited susceptibility to viral transduction, and the genomic perturbations arising from random integration are even more difficult to dilute or eliminate in primary cells with a finite lifespan. Immortalized HUVECs—such as those engineered with SV40T large T antigen or hTERT—when combined with lentivirus‑based CRISPR libraries, enable scalable whole‑genome screening; however, this essentially shifts the challenge to an immortalized cellular context, and the fidelity of the endothelial phenotype must be independently validated.
RNP electroporation represents the most feasible approach for primary HUVECs at present. Nuclear delivery of the Cas9 protein–sgRNA complex (RNP) bypasses DNA vectors and viral integration; following transient expression, the nuclease is degraded, thereby reducing the accumulation of off-target effects associated with sustained expression. Studies have shown that, at the HIF1A locus, RNP electroporation achieved 98% biallelic knockout without any selection pressure, with editing efficiency far exceeding that of plasmid delivery. These data suggest that, in primary HUVECs, the main bottleneck to genome editing lies in the delivery method rather than an intrinsic inability of the cells to be edited. For aging‑related genes such as KNDC1, CRISPR/Cas9‑mediated knockout has also been employed to investigate anti‑aging phenotypic changes in HUVECs.
Liman Bio has optimized HUVEC cell transfection conditions through extensive experimentation, employing chemically modified sgRNAs and delivering RNP complexes into cells via electroporation or an enhanced transfection protocol, achieving a polyclonal editing efficiency of up to 100%. Targeted gene editing can be completed in just three days, helping you overcome technical bottlenecks and accelerate scientific breakthroughs.
Below are selected examples of HUVEC gene knockouts at LIMAN Bio, along with our stock cell lines. (Please contact LIMAN to inquire about available stock cell lines or to request custom HUVEC knockout cell lines.)
| Target gene |
Cell line |
KO efficiency |
DNA sequencing results |
Impact on proteins |
| Klf2 |
HUVEC |
100% |
Compared with the wild-type sequence, early exons exhibit either fragment loss or frameshift mutations. |
Causes premature termination of translation at the N-terminus of the protein |
| KAT2A |
HUVEC |
100% |
Compared with the wild-type sequence, early exons exhibit either fragment loss or frameshift mutations. |
Causes premature termination of translation at the N-terminus of the protein. |
6. References
1. Medina-Leyte DJ, Domínguez-Pérez M, Mercado I, et al. Use of human umbilical vein endothelial cells (HUVEC) as a model to study cardiovascular disease: A review. Applied Sciences. 2020;10(3):938.
2. Nachman RL, Jaffe EA. Endothelial cell culture: beginnings of modern vascular biology. J Clin Invest. 2004;114(8):1037-1040.
3. Endothelial Senescence: From Macro- to Micro-Vasculature and Its Implications on Cardiovascular Health. PMC. 2024.
4. Exogenous Hydrogen Sulfide Activates PI3K/Akt/eNOS Pathway to Improve Replicative Senescence in Human Umbilical Vein Endothelial Cells. Oxidative Medicine and Cellular Longevity. 2023;2023:7296874.
5. Prigozhina NL, et al. Characterization of a novel angiogenic model based on stable fluorescently labeled endothelial cell lines. CIRM. 2011.
6. Angiogenic profiling and comparison of immortalized endothelial cells for functional genomics. ScienceDirect. 2007.
7. Stepwise Optimization of a Matrigel-Based In Vitro Angiogenesis Assay for Reproducible and Quantifiable 2D-Tube Formation Using HUVECs. Methods in Molecular Biology. 2026.
8. Chen X, Chen B, Yang Y, et al. Isolation, culture and identification of human umbilical vein endothelial cells.
9. Gong X, et al. Efficient Gene Disruption in Cultured Primary Human Endothelial Cells by CRISPR/Cas9. Circulation Research. 2015;117(2):121-128. 10. HIF1A Knockout by Biallelic and Selection-Free CRISPR Gene Editing in Human Primary Endothelial Cells with Ribonucleoprotein Complexes. Biomolecules. 2023;13(1):23.
11. Human umbilical vein endothelial cells with CRISPR/Cas9–mediated knockout of KNDC1 exhibit anti‑aging properties. Basic Medicine and Clinical Practice. 2020;(9).
12. Schwefel K, et al. Biallelic CCM3 mutations cause a clonogenic survival advantage and endothelial cell stiffening. J Cell Mol Med. 2019;23:1771.
2026 /
11-02
Classification:
News
Related Information